Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
Evid Based Complement Alternat Med. 2011;2011:915051. doi: 10.1093/ecam/neq061. Epub 2011 Apr 14.
San-Huang-Xie-Xin-Tang (SHXT) is a traditional Chinese medication consisting of three herbs, namely Coptidis rhizome, Scutellariae radix and Rhei rhizome. This study aimed to examine the cardioprotective effects of SHXT in a rat model of acute myocardial apoptosis induced by ischemia/reperfusion (I/R). Vehicle (intravenous saline) or SHXT (intravenous or oral) was administered prior to I/R (occlusion of left coronary artery for 45 min followed by reperfusion for 2 h). In the vehicle group, myocardial I/R caused myocardial infarction with increased plasma cardiac enzymes, severe arrhythmia and mortality. Myocardial apoptosis was induced by I/R as evidenced by DNA ladder and Bcl-2/Bax ratio. In the SHXT group, we found that SHXT significantly reduced plasma levels of cardiac enzymes, arrhythmia scores (from 5 ± 1 to 2 ± 1, P < .01) and mortality rate (from 53 to 0%, P < .01). In addition, pretreatment with intravenous SHXT reduced the infarct size dose-dependently when compared with the vehicle group (10 mg kg(-1): 14.0 ± 0.2 versus 44.5 ± 5.0%, and 30 mg kg(-1): 6.2 ± 1.2% versus 44.5 ± 5.0%, both P < .01). Similarly, oral administration of SHXT reduced the infarct size dose-dependently. Furthermore, SHXT markedly decreased the apoptosis induced by I/R with increased Bcl-2/Bax ratio. Finally, we found that SHXT counteracted the I/R-induced downstream signaling, resulting in increased myocardial eNOS expression and plasma nitrite, and decreased activation of ERK1/2, p38 and JNK. These data suggest that SHXT has cardioprotective effects against I/R-induced apoptosis, and that these effects are mediated, at least in part, by eNOS and MAPK pathways.
三黄泻心汤由三种草药组成,分别是黄连、黄芩和大黄。本研究旨在探讨三黄泻心汤(SHXT)对缺血/再灌注(I/R)诱导的急性心肌细胞凋亡大鼠模型的心脏保护作用。在 I/R 前给予载体(静脉生理盐水)或 SHXT(静脉或口服)。在载体组中,心肌 I/R 导致心肌梗死,同时伴有血浆心肌酶升高、严重心律失常和死亡率增加。I/R 诱导的心肌细胞凋亡表现为 DNA 梯状条带和 Bcl-2/Bax 比值升高。在 SHXT 组中,我们发现 SHXT 可显著降低血浆心肌酶水平、心律失常评分(从 5 ± 1 降至 2 ± 1,P <.01)和死亡率(从 53%降至 0%,P <.01)。此外,与载体组相比,静脉内给予 SHXT 可剂量依赖性地减少梗死面积(10 mg·kg(-1):14.0 ± 0.2 比 44.5 ± 5.0%,30 mg·kg(-1):6.2 ± 1.2%比 44.5 ± 5.0%,均 P <.01)。同样,口服给予 SHXT 也可剂量依赖性地减少梗死面积。此外,SHXT 可显著减少 I/R 诱导的凋亡,同时增加 Bcl-2/Bax 比值。最后,我们发现 SHXT 可拮抗 I/R 诱导的下游信号转导,导致心肌 eNOS 表达和血浆亚硝酸盐增加,同时减少 ERK1/2、p38 和 JNK 的激活。这些数据表明,SHXT 对 I/R 诱导的凋亡具有心脏保护作用,其作用至少部分是通过 eNOS 和 MAPK 途径介导的。